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Abstract
Background: Because of the development of resistance in trypanosomes to trypanocidal drugs, the livelihood of millions of
livestock keepers in sub-Saharan Africa is threatened now more than ever. The existing compounds have become virtually
useless and pharmaceutical companies are not keen on investing in the development of new trypanocides. We may have
found a breakthrough in the treatment of resistant trypanosomal infections, through the combination of the trypanocide
isometamidium chloride (ISM) with two affordable veterinary antibiotics.
Methodology/Principal Findings: In a first experiment, groups of mice were inoculated with Trypanosoma congolense
strains resistant to ISM and either left untreated or treated with (i) tetracycline, (ii) ISM or (iii) the combination of the
antibiotic and the trypanocide. Survival analysis showed that there was a significant effect of treatment and resistance to
treatment on the survival time. The groups treated with ISM (with or without antibiotic) survived significantly longer than
the groups that were not treated with ISM (P,0.01). The group treated with the combination trypanocide/antibiotic
survived significantly longer than the group treated with ISM (P,0.01). In a second experiment, groups of cattle were
inoculated with the same resistant trypanosome strain and treated with (i) ISM, (ii) ISM associated with oxytetracycline or (iii)
ISM associated with enrofloxacine. All animals treated with ISM became parasitaemic. In the groups treated with ISM-
oxytetracycline and ISM-enrofloxacine, 50% of the animals were cured. Animals from the groups treated with a combination
trypanocide/antibiotic presented a significantly longer prepatent period than animals treated with ISM (p,0.001). The
impact of the disease on the haematocrit was low in all ISM treated groups. Yet, it was lower in the groups treated with the
combination trypanocide/antibiotic (p,0.01).
Conclusions/Significance: After optimization of the administration protocol, this new therapeutic combination could
constitute a promising treatment for livestock infected with drug resistant T. congolense.
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Introduction
African Animal Trypanosomiasis affects about 10 million km
2
of sub-Saharan Africa and is a primary cause of rural poverty and
food insecurity as explicitly recognized by the African Union,
FAO and others [1]. Tsetse and the disease they transmit will
continue to be a considerable threat to livestock and rural
development [2]. Over the years, a large arsenal of vector control
tools has been developed but they are difficult to sustain at the
smallholder level. Hence, the control of animal trypanosomiasis
(mainly Trypanosoma congolense) and zoonotic Human African
Trypanosomiasis (mainly T. brucei rhodesiense) in poor rural
communities has and will continue to rely heavily on the use of
trypanocidal drugs. However, the development of trypanocidal
drug resistance in T. congolense was reported in 17 countries of
sub-Saharan Africa [3] and is becoming a huge threat for the
cattle breeders in many regions. On the Adamaoua plateau in
Cameroon, for example, up to 100% of the tested trypanosome
isolates were found resistant to isometamidium chloride (ISM)
and to diminazene aceturate (DA) leaving farmers helpless [4].
Unfortunately, no new drug is expected to be available in the
near future and resistance is spreading very rapidly. For example,
a five fold increase in DA resistance within a seven years interval
was observed in the Eastern Province of Zambia [5]. Hence,
alternatives are urgently needed to circumvent trypanocidal drug
resistance.
www.plosntds.org 1 September 2010 | Volume 4 | Issue 9 | e828Reversal of drug resistance or chemosensitization was success-
fully achieved, among others, in yeast [6], Plasmodium [7,8], cancer
cells [9] and Leishmania [10]. Such strategies could bring a much
needed relief to African livestock breeders if they could be
implemented at a reasonable price by shortcutting the develop-
ment of new compound, toxicity studies and long clinical trials.
Many bacterial secondary multidrug resistance transporters belong-
i n gt ot h et w om a j o rf a m i l i e s ,i . e .t he Major Facilitator Superfamily
(MFS) and the Multi Antimicrobial Extrusion Family (MatE) are
described as having affinity for ethidium bromide (Homidium) as well
as for many different compounds such as plant alkaloids, noxious
metabolic products (such as fatty acids or bile salts), organic solvents
and diverse antibiotics [11]. At least eight representatives of those
transporters families are present in the genome of T. congolense.
Homidium is part of the ISM molecule, the structural
relatedness of both molecules being thus obvious (Figure 1).
Furthermore, in the field, cross-resistance is observed between
ethidium bromide and ISM [12] suggesting that uptake and
extrusion of the drug within and from the trypanosome are
mediated by the same mechanisms for both compounds.
Hence, our working hypothesis is that chemical compounds could
interfere (compete) with the extrusion of ISM from the drug resistant
trypanosome allowing a prolonged trypanocidal action. The
objective ofthisworkwastobringsomeindirectevidenceconfirming
this working hypothesis. Preliminary experiments conducted in vitro
would have allowed a more precise definition of the role of those
secondary transporters in trypanocidal drug resistance but research
in this domain is hampered by the fact that except for some atypical
laboratory strains, bloodstreams forms of T. congolense do not grow
properlyinvitro[13–15].Seekingacommerciallyavailablechemical
compound that could be used for treating livestock, a number of
antibiotics were selected and screened in a mouse model. The
criterion for inclusion inthis study was the affinity of the medications
for bacterial efflux systems as described for b-lactams [16,17],
tetracycline (TC), oxytetracycline (OTC) [18], nalidixic acid
(quinolone) [19] and the fluoroquinolone enrofloxacine (FQE)
[20]. The nalidixic acid and b-lactam (Penicilline G) were rejected
after preliminary experiments (see table 1), no difference being
observed between groups treated with ISM alone or treated with
ISM associated with one of the two compounds. The absence of
curative effects of the antibiotics used alone was consistently checked
in a mouse model (see table 1). After this preliminary screening,
OTC was selected for the experiment in cattle as it is available as an
injectable long acting form allowing for a reduction of the number of
injections. For the experiment in mouse, TC was chosen as the
easiest and cheapest commercial preparation for oral administration
by dilution in drinking water. Enrofloxacin was not pre-tested in
combination with ISM in mice but immediately used in cattle.
Materials and Methods
Ethics statement
This is to certify that the experiments carried out at the Institute
of Tropical Medicine in the framework of the hereunder
mentioned study were approved by the Ethics Committee of the
Institute of Tropical Medicine and that the study was conducted
adhering to the institutional guidelines for animal husbandry. In
Belgium protection of experimental animals is regulated by the
Royal Decision of 14/11/1993. Article 3bis paragraph 1 of this
Royal Decision stipulates that: Every laboratory that keeps
vertebrates with a view to perform experiments that may cause
pain, suffering or lesions, has to establish an Ethics Committee.
The Ethics Committee is composed of at least 6 members. The
laboratory director or his representative, the leaders of the
experiments, some laboratory assistants and the veterinary surgeon
or the expert charged with the supervision of the health and the
well-being of the animals are part of the Ethics Committee.
Moreover one or more independent members, not belonging to
the laboratory staff, will be member of the Committee. A
veterinary inspector of the Ministry of Agriculture will also have
a seat on the Ethics Committee. Identification of the experiment:
DG008-VD-M-Tryp Title of the project: Study on the genetic
basis and improved detection methods of resistance against
isometamidium and diminazene in animal trypanosomes. Date
of reception of the application: 03/11/2008 Date of approval by
the Ethical Commission: 23/12/2008 (extension of a similar
application DG006-VD-M-Tryp approved in 2004) Validity of
this approval: from 23/12/2008 until 22/12/2012.
Trypanosome strains
The cloned T. congolense savannah type strain IL3343 was
identified as resistant to ISM when tested in mice (CD50=
1.7 mg/kg) [21] with the CD50 defined as the curative dose that
gives complete cure in 50% of the animals.
The T. congolense savannah type strain TRT57C10 was isolated
from cattle in Eastern Zambia in 1996, cloned and conserved as a
stabilate in liquid nitrogen. It was identified as highly resistant to
ISM when tested in mice. Three doses of ISM, i.e. 0.1, 1 and
10mg/kg were tested according to the protocol described by Eisler
et al. [22]. When treated with 10mg/kg ISM, 100% of the mice
relapsed (CD50.10mg/kg).
Mice inoculation and treatment
The stabilates of the cloned isolates were reactivated in mice.
When the parasitaemia reached 8 on Herbert and Lumsden’s scale
[23], blood was collected under terminal anaesthesia by heart
puncture and 4 groups of 16 adult OF1 mice weighing on average
30g each were inoculated with one of the two trypanosome clones
(5*10
5 trypanosomes/mouse through intraperitoneal injection).
Twenty four hours after inoculation and for each clone, group 1
was left untreated and served as control, group 2 was treated for 30
days, per os, with 125mg/kg/day tetracycline, group 3 was treated
Author Summary
African Animal Trypanosomiasis causes the death of 3
million head of cattle each year. The annual economic
losses as a result of the disease are estimated to be 4.5
billion US dollars. Trypanosomes are transmitted by tsetse
flies and can infect a wide range of hosts from wildlife to
domestic animals. This study is dealing with Trypanosoma
congolense, which is one of the very prevalent parasites
affecting livestock of poor African rural communities,
decreasing the milk and meat production but also
reducing the fitness of cattle that is used as draught
power. Infected animals can only be treated by three
compounds, i.e., diminazene, isometamidium and ethi-
dium. These three products have been in use for more
than a half century and it is thus not surprising to observe
treatment failures. In some areas, the trypanosomes
circulating have developed resistance to the three drugs
leaving the farmers with no further options. As pharma-
ceutical companies are not keen on investing efforts and
money in the development of new veterinary drugs for
this low-budget market, our idea was to render an old
ineffective drug effective again by combining it with
existing potentiating compounds that are available and
affordable for the livestock keeper.
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group 4 was treated with 1mg/kg ISM injected once intraperi-
toneally and was treated per os with 125mg/kg/day TC for 30
days. Mean water consumption of the mice was determined before
and during the experiment and was on average of 3ml/day/mouse
at 18uC. This water intake was not affected by the presence of TC
in the drinking water. All mice were monitored three times a week
for survival and presence of trypanosomes by microscopic
examination of a wet film made from fresh blood sampled from
the tail of each mouse for a period of 140 days.
Mice were euthanized when their health status, determined by
clinical examination, was deteriorating (prostration, lateral decu-
bitus, hyperventilation, unconsciousness and/or PCV#20).
At day 140, all surviving mice were euthanized and between 1.5
and 2ml blood was collected. The DNA of the whole blood sample
was then extracted using a routine phenol–chloroform–isoamyl
alcohol method [24]. To confirm the presence or absence of
trypanosomes, the PCR technique on the 18S small subunit of the
ribosomal DNA (Ssu-rDNA) was used [25,26].
Cattle inoculation and treatment
5Three groups of 6 adult crossbred zebus weighing on average
158 kg each (extremes 140 and 201kg) were inoculated with
5610
5 trypanosomes (cloned isolate IL3343) each by intra-jugular
injection 30 days after treatment with DA (7mg/kg) to clear all
trypanosomal infections and deworming. One non-treated control
group of 2 cattle was inoculated in the same way. The 20 cattle
were housed in fly-proof facilities. From day 7 after the
inoculation, all animals were monitored 2 times a week during
95 days. Their PCV was measured and jugular blood was
Figure 1. Structural relatedness between isometamidium and ethidium salts.
doi:10.1371/journal.pntd.0000828.g001
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tion of the buffy coats and by PCR [25] performed on buffy coats
collected on on Whatman 4 filter paper (Whatman). The DNA
was obtained using a routine chelex-based extraction method [24].
At the first parasitaemia, group A was treated with one single
administration of 0.5mg/kg ISM by intramuscular (IM) injection,
group B with one single administration of 0.5mg/kg ISM and with
20mg/kg OTC (Terramycin LA) IM every 3 days for 30 days and
group C with one single administration of 0.5mg/kg ISM and with
5mg/kg FQE (Baytril 100) IM every 2 days for 30 days. For each
animal, the injection sites of the drugs were alternatively selected
in forehand and hindquarters, shaved and coloured with
methylene blue and picric acid for OTC and FQE respectively.
A minimal distance of 6 cm between injection sites was respected.
Statistical analysis
The survival of the mice in the 8 groups and of the cattle in the
three groups was analysed in two separate survival models in Stata
10 (Copyright 1996–2009 StataCorp LP) using groups as an
explanatory variable. A log-normal distribution was used in a
parametric model (Text S1). The start of the model corresponded
to the day of inoculation and the experiment was short enough to
ignore natural mortality of animals.
The cattle’s PCV values were analyzed using a cross-sectional
linear regression, accounting for repeated measures from individ-
ual animals. Explanatory variables were the animal groups, post-
treatment periods and the interactions between them. Three post-
treatment periods each containing the same number of samplings
were defined as follows: day 1–21, day 22–54 and day 55–98. The
interaction term between the groups and the third period (using
the first period as a baseline) was used as indicator of the impact of
the disease on the PCV.
Results and Discussion
Experiment in mice
A significant effect of treatment and resistance to treatment on
the survival time of the mice was observed. The data are
summarized in table 2. Groups 3 and 4 survived significantly
longer than group 1 (control without treatment; P,0.01), unlike
group 2 (received only TC as treatment; P.0.1). The longer
survival time of the mice treated with ISM with or without
potentiator is confirming our field observations that even when
trypanocidal drug resistance is present, ISM seems to impair the
development of the parasite, reducing the impact of the disease on
the health of the infected animal.
For both strains, resistant (IL3343) and highly resistant
(TRT57C10), there was a significant difference between groups 3
(ISM treatment only) and 4 (treated with ISM and TC; P,0.01)
(Figure 2 and Figure 3). When considering the efficacy of the
compounds against the trypanosomes, the complete ineffectiveness
of TC alone and the increased efficacy of ISM in presence of TC,
provides strong arguments in favor of the hypothesis that the two
compounds compete for the same efflux system.
Despite the unusual high degree of resistance of T. congolense
TRT57C10, the survival times were significantly higher after
treatment with the association of ISM and TC. One mouse
survived the infection for 140 days. Such a high survival time was
never observed before in laboratory experiments using this strain.
Furthermore, the PCR analysis of the blood sample at day 140 was
negative suggesting that the trypanosomal infection was cleared
completely. Moreover, the blood sample used for diagnosis was
between 1.5 and 2ml of blood representing the average total
amount of blood that can be collected from a mouse. Since the
sensitivity of the diagnostic method is 25 trypanosomes/ml [25],
Table 1. Initial screening of antibiotics in a mouse model
(Trypanosoma congolense strain IL3343).
Treatment Cured
Median PP
(days)
95% confidence
intervals
Untreated control 0/6 5,41 4,10–7,16
Penicilline G (100mg/kg) 0/6 5,79 4,38–7,77
Nalidixic acid (175mg/kg) 0/6 6,29 4,76–8,32
Tetracycline (125mg/kg) 0/6 6,80 5,14–8,99
Oxytetracycline (125mg/kg) 0/6 5,06 3,83–6,69
Enrofloxacine (40mg/kg) 0/6 5,22 3,95–6,90
ISM (1mg/kg) 0/6 16,29 12,32–21,53
ISM/Penicilline G (*) 0/6 12,27 9,28–16,22
ISM/Nalidixic acid 0/6 16,73 12,66–22,13
ISM/Tetracycline 4/6 51.96 38.01–71.05
ISM/Oxytetracycline 3/6 39.1 29.16–52.43
ISM/Enrofloxacine N.T. - -
(*) ISM at 1mg/kg combined to the antibiotic at the dose used alone; N.T.: Not
Tested.
doi:10.1371/journal.pntd.0000828.t001
Table 2. Summarized data of the output of the treatments in mice.
Group 1 (control) Group 2 (TC) Group 3 (ISM) Group 4 (ISM-TC)
TRT57C10
Number of animals 16 16 16 16
Median PP (days) 5,7 (4,2–7,8) 5,8 (4,3–7,9) 10,8 (8,0–14,8) 14,5 (10,6–19,7)
Median ST (days) 9,6 (7,9–11,8) 9,5 (7,8–11,6) 13,8 (11,3–16,9) 20,2 (16,5–24,7)
Cured 0 0 0 1
IL3343
Number of animals 16 16 16 16
Median PP (days) 4,3 (3,2–5,9) 4,1 (3,0–5,6) 86.3 (61.4–121) 249 (153–405)
Median ST (days) 8,2 (6,7–10,0) 8,5 (7,0–10,4) 134 (106–172) 244 (169–355)
Cured 0 0 13 15
doi:10.1371/journal.pntd.0000828.t002
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ISM: group 3; ISM-TC: group 4.
doi:10.1371/journal.pntd.0000828.g002
Figure 3. Kaplan-Meier survival estimates in mice infected with the resistant strain IL3343. UC: group 1 Untreated Control; TC: group 2;
ISM: group 3; ISM-TC: group 4.
doi:10.1371/journal.pntd.0000828.g003
Chemosensitization of Drug Resistant Trypanosomes
www.plosntds.org 5 September 2010 | Volume 4 | Issue 9 | e828the complete absence of trypanosomes and thus, the complete
clearance of the parasites from the host can reasonably be assumed.
For the resistant strain (IL3343), in group 3, among the 13
surviving mice, 3/13 were microscopically positive for the
presence of trypanosomes and 6/13 were positive for the presence
of trypanosomes by PCR. In group 4, among the 15 surviving
mice, 1/15 was microscopically positive for the presence of
trypanosomes and 3/15 were positive for the presence of
trypanosomes by PCR.
Experiment in cattle
The two untreated control animals became parasitaemic 11
days after inoculation and were treated with DA (7 mg/kg) on day
30 because their PCV reached the critical value of 25.
All 6 animals of group A (ISM) became positive between days
24 and 46 post-inoculation. The data are summarized in table 3.
When ISM was used in combination with either OTC (group B) or
FQE (group C), the prepatent period was significantly longer
(p,0.001; Figure 4). 50% of the cattle became infected (between
days 46 and 82) and 50% completely cleared the infection. In the
groups B (ISM-OTC) and C (ISM-FQE), the parasitaemia
remained very low, below the detection level of the microscopic
examination, i.e. 450 trypanosomes/ml [27]. The PCR results
were fluctuating with animals being detected parasitaemic every 2
to 3 weeks, indicating a parasitaemia oscillating just above and
below the detection limit of the PCR test, i.e. 25 trypanosomes/ml
blood [25].
The impact of the infection on the PCV was not very
pronounced, even in group A (average PCV reduction 8 to 14
weeks after treatment: 5.9%; 95% CI: 4.5–7.3). However, this
impact was lower in groups B (ISM-OTC) and C (ISM-FQE)
compared to group A (ISM) (p,0.01). These observations indicate
that even in the case of ISM-resistant trypanosomes, farmers still
seem to benefit from the use of the trypanocide because of the
significant decrease of the effect of the infection on the health
status of the animals as represented in the PCV values.
Figure 4. Kaplan-Meier survival estimates in cattle infected with the resistant strain IL3343. ISM: group A; ISM-OTC: group B; ISM-FQE:
group C.
doi:10.1371/journal.pntd.0000828.g004
Table 3. Summarized data of the output of the treatments in cattle.
Group A (ISM) Group B (ISM-OTC) Group C (ISM-FQE)
Number of animals 66 6
Median prepatent period (days) 35 (26–47) 84 (61–117) 91 (66–127)
Mean PCV drop from period 1 to period 3 5.9 (4.5–7.3) 1.8 (0.3–3.2) 3.3 (1.9–4.7)
Cured 03 3
doi:10.1371/journal.pntd.0000828.t003
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Although resistance to DA and ISM, is developing quickly
[5,28,29], controlling the parasite in livestock using drugs remains
the control method of choice for small-scale livestock breeders.
Localised tsetse control is usually not effective [30] and a vaccine is
not yet available, leaving little choice to control the disease.
Trypanosomiasis not only affects livestock production (milk, meat)
but also impacts greatly on crop production through the inability
to keep draft animals in tsetse-infested areas [31]. Notwithstanding
the alarming levels of trypanocidal drug resistance that have been
reported in the cotton belt of West Africa [32] and in some regions
of southern Africa (including Zambia) [4,5], new trypanocidal
drugs for animal use are not expected to become available in the
near future. Pharmaceutical companies do not invest in research
and development of new veterinarian trypanocidal compounds for
a too specific, limited African market with poor benefit
perspectives [33]. Hence, potentiating the available trypanocidal
drugs may represent a powerful alternative to the current
problems associated with the control of trypanosomes in livestock.
Research in the field of non-competitive inhibitors of efflux pumps
in bacteria is being conducted [34–36] and may ultimately
represent an immense hope for future control of trypanosomiasis
using drugs. In the meantime, TC and some derivatives are cheap
drugs, registered for use in livestock, widely available on the
African market and with an expired patent, now in the public
domain. More importantly, TC is commonly used by African
farmers and will not require elaborate new chemistry and safety
tests. Hence, assuming that further trials confirm the effectiveness
of the antibiotics in potentiating the activity of trypanocidal drugs
in cattle under natural tsetse challenge, the new control approach
can be implemented rapidly. It is likely that the combination ISM–
TC/OTC can also be made more cost effective after adjusting
dosage and the duration of the treatment. Furthermore, several
analogues of TC/OTC and FQE are available albeit somewhat
more expensive as patents are still in force. These compounds are
currently being screened with the aim of optimizing the delivery
system to increase the specificity of the treatment, to boost the
intracellular concentration of the chemosensitizer within the
trypanosome and to reduce the dose. Obviously, the current
treatment schedule cannot be used under field conditions. The
repeated administration of a high dose of antibiotics is far too
expensive for the rural communities and would certainly render
the treated animals unsuitable for human consumption. Further
research is thus ongoing to identify the best galenic solution, the
optimal combination of chemosensitizer with ISM (qualitative and
quantitative) and to test this combination in livestock under
controlled and field conditions in areas with high tsetse challenge
and high trypanocidal drug resistance. An effective combination of
ISM and chemosensitizer(s) should result in (i) a decrease in the
proportion of circulating strains resistant to ISM and (ii) a decrease
in the impact of the disease on the health status of the cattle.
Strategic use of this approach may result in an increased efficacy of
currently available trypanocidal drugs in extensive areas of sub-
Saharan Africa where their use is severely curtailed as a result of
the development of resistance in trypanosomes.
Supporting Information
Text S1 [Statistics] Model of the overall hazard as a function of
time using an exponential mode.
Found at: doi:10.1371/journal.pntd.0000828.s001 (0.02 MB
DOC)
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